Tyrosine kinase inhibitorPhase 3 trialInvestigational
Cabozantinib
How it works
Blocks the activity of certain enzymes that help cancer cells grow and divide.
Cancer types
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Two Cancer Treatments Shows Promise in Advanced Melanoma | Melanoma | phase-1/2 | Among 20 patients treated in phase 2, the overall response rate was 45%, median progression-free survival was 6.6 months, and median overall survival was 29.5 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.